Inactive Instrument

Mallinckrodt plc

MNK

IE000O3L0NQ3

Mallinckrodt plc Reports Earnings Results for the Second Quarter and Six Months Ended July 01, 2022

August 11, 2022 at 06:06 am EDT

Mallinckrodt plc reported earnings results for the second quarter and six months ended July 01, 2022. For the second quarter, the company reported sales was USD 468.7 million compared to USD 546.4 million a year ago. Net loss was USD 257.2 million compared to USD 105.8 million a year ago.
For the six months, sales was USD 959.6 million compared to USD 1,104.4 million a year ago. Net loss was USD 376.8 million compared to USD 249.7 million a year ago.

Latest news about Mallinckrodt plc

Mallinckrodt plc Reports Earnings Results for the Full Year Ended December 29, 2023	Mar. 26	CI
Mallinckrodt plc Reports Earnings Results for the Fourth Quarter Ended December 29, 2023	Mar. 26	CI
Mallinckrodt plc Provides Earnings Guidance for the Year 2024	Mar. 26	CI
Mallinckrodt Appoints Paul O'neill as Executive Vice President, Quality & Operations, Specialty Brands	Mar. 04	CI
Mallinckrodt plc Announces FDA Clearance of the INOmax® EVOLVE? DS Delivery System and Approval of the INOmax® Mini-Cylinder	Dec. 07	CI
Mallinckrodt plc Announces Resignation of Sigurdur Olafsson as Chief Executive Officer	Nov. 15	CI
Mallinckrodt plc Announces Board Changes	Nov. 15	CI
Drugmaker Mallinckrodt emerges from bankruptcy	Nov. 14	RE
Drugmaker Mallinckrodt emerges from bankruptcy	Nov. 14	RE
Mallinckrodt plc Emerged from Bankruptcy	Nov. 13	CI
Mallinckrodt plc to Present Breadth of Data on Terlivaz (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome At the American Association for the Study of Liver Diseases 2023 Liver Meeting	Nov. 08	CI
Mallinckrodt plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 29, 2023	Nov. 07	CI
Mallinckrodt plc Revises Earnings Guidance for the Full-Year of 2023	Nov. 07	CI
Mallinckrodt Presents Latest Health Economics Data on Acthar Gel (Repository Corticotropin Injection) At the Academy of Managed Care Pharmacy Nexus 2023	23-10-26	CI
Rite Aid joins companies going bankrupt amid opioid litigation	23-10-16	RE
Drug retailer Rite Aid files for bankruptcy, gets $3.45 bln commitment	23-10-15	RE
U.S. Inflation Might Settle Above Target; Fed Is -2-	23-10-13	DJ
News Highlights : Top Company News of the Day	23-10-10	DJ
Mallinckrodt gets court approval for restructuring, $1 bln cut to opioid settlement	23-10-10	RE
MALLINCKRODT GETS COURT APPROVAL FOR RESTRUCTURING, $1 BLN CUT T…	23-10-10	RE
Mallinckrodt Announces Publication of Two Journal Manuscripts with Clinical and Economic Evidence for Acthar Gel (Repository Corticotropin Injection)	23-10-10	CI
First Amended Reorganization Plan Approved for Mallinckrodt plc	23-10-10	CI
First Amended Joint Reorganization Plan Filed by Mallinckrodt plc	23-09-29	CI
Final DIP Financing Approved for Mallinckrodt plc	23-09-21	CI
Health Care Flat Amid Inflation Bets -- Health Care Roundup	23-09-19	DJ

Chart Mallinckrodt plc

Duration

Period

More charts

Company Profile

Mallinckrodt plc develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies. The Company operates in two reportable segments: Specialty Brands and Specialty Generics. The Specialty Brands includes specialty pharmaceutical brands. The Specialty Generics includes niche specialty generic drugs and active pharmaceutical ingredients. Its Specialty Generics segment is focused on providing its customers with specialty generic drugs and active pharmaceutical ingredients (APIs). The Company focuses on various therapeutic areas, such as autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics, cultured skin substitutes and gastrointestinal products. Its product portfolio includes Acthar Gel, INOmax, Therakos photopheresis, StrataGraft, Terlivaz, and Amitiza.

Sector

Pharmaceuticals

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.61%	660B
NOVO NORDISK A/S	+22.45%	562B
JOHNSON & JOHNSON	-5.24%	358B
MERCK & CO., INC.	+16.49%	322B
ABBVIE INC.	+8.28%	297B
ASTRAZENECA PLC	+12.94%	219B
ROCHE HOLDING AG	-9.69%	196B
NOVARTIS AG	+6.54%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals